Technical Data
B2553-06F
Bone Morphogenetic Protein 2, Recombinant, Human (BMP2, BMP-2, Bone Morphogenetic Protein 2A, BMP2A, BMP-2A)
2ug
|
Technical Data |
|
B2553-06F |
Bone Morphogenetic Protein 2, Recombinant, Human (BMP2, BMP-2, Bone Morphogenetic Protein 2A, BMP2A, BMP-2A) |
2ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 115aa of human Bone Morphogenetic Protein -2 expressed in E.coli is a homodimeric, non-glycosylated, Polypeptide chain. Molecular Weight: ~26kD Biological Activity: The ED50 as determined by the cytolysis of MC3T3-E1 cells is less then 50nug/ml Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.4 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of BMP-2 as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~26kD |
Purity: ~95% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~1mg/ml Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Histological analysis of a displaced femoral ring allograft spacer filled with a recombinant human bone morphogenetic protein-2-soaked collagen sponge. A case report. J Bone Joint Surg Am 2005 Oct;87(10):2318-22. 2. Expression of bone morphogenetic protein 2 in normal spontaneous labor at term, preterm labor, and preterm premature rupture of membranes. Am J Obstet Gynecol 2005 Sep;193(3 Pt 2):1137-43. 3. Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft? Acta Orthop Belg 2005 Apr;71(2):133-48. 4. Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J Neurosurg Spine 2005 Jul;3(1):47-52. 5. Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells. J Biomed Mater Res A 2005 Oct 1;75(1):210-5. 6. Tissue engineering with recombinant human bone morphogenetic protein-2 for alveolar augmentation and oral implant osseointegration: experimental observations and clinical perspectives. Clin Implant Dent Relat Res 2005;7(2):112-9.
|
||